COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic Journal Article

Authors: Lara, O. D.; Smith, M.; Wang, Y.; O'Cearbhaill, R. E.; Blank, S. V.; Kolev, V.; Carr, C.; Knisely, A.; McEachron, J.; Gabor, L.; Chapman-Davis, E.; Cohen, S.; Fehniger, J.; Lee, Y. C.; Isani, S.; Liu, M.; Wright, J. D.; Pothuri, B.
Article Title: COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic
Abstract: Background: Despite significant increase in COVID-19 publications, characterization of COVID-19 infection in patients with gynecologic cancer remains limited. Here we present an update of COVID-19 outcomes among people with gynecologic cancer in New York City (NYC) during the initial surge of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019 [COVID-19]). Methods: Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 NYC area hospital systems between March and June 2020. Multivariable logistic regression was utilized to estimate associations between factors and COVID-19 related hospitalization and mortality. Results: Of 193 patients with gynecologic cancer and COVID-19, the median age at diagnosis was 65.0 years (interquartile range (IQR), 53.0–73.0 years). One hundred six of the 193 patients (54.9%) required hospitalization; among the hospitalized patients, 13 (12.3%) required invasive mechanical ventilation, 39 (36.8%) required ICU admission. Half of the cohort (49.2%) had not received anti-cancer treatment prior to COVID-19 diagnosis. No patients requiring mechanical ventilation survived. Thirty-four of 193 (17.6%) patients died of COVID-19 complications. In multivariable analysis, hospitalization was associated with an age ≥ 65 years (odds ratio [OR] 2.12, 95% confidence interval [CI] 1.11, 4.07), Black race (OR 2.53, CI 1.24, 5.32), performance status ≥2 (OR 3.67, CI 1.25, 13.55) and ≥ 3 comorbidities (OR 2.00, CI 1.05, 3.84). Only former or current history of smoking (OR 2.75, CI 1.21, 6.22) was associated with death due to COVID-19 in multivariable analysis. Administration of cytotoxic chemotherapy within 90 days of COVID-19 diagnosis was not predictive of COVID-19 hospitalization (OR 0.83, CI 0.41, 1.68) or mortality (OR 1.56, CI 0.67, 3.53). Conclusions: The case fatality rate among patients with gynecologic malignancy with COVID-19 infection was 17.6%. Cancer-directed therapy was not associated with an increased risk of mortality related to COVID-19 infection. © 2021 Elsevier Inc.
Keywords: gynecologic cancer; outcomes; coronavirus disease 2019 (covid-19); severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
Journal Title: Gynecologic Oncology
Volume: 164
Issue: 2
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2022-02-01
Start Page: 304
End Page: 310
Language: English
DOI: 10.1016/j.ygyno.2021.12.004
PUBMED: 34922769
PROVIDER: scopus
PMCID: PMC8648583
Notes: Article -- Export Date: 1 February 2022 -- Source: Scopus
Citation Impact
MSK Authors
  1. Seth Matthew Cohen
    10 Cohen